This study is designed to assess the safety, tolerability, efficacy and pharmacokinetics (PK)
of NS-065/NCNP-01 in subjects diagnosed with Duchenne muscular dystrophy (DMD).
Phase:
Phase 1
Details
Lead Sponsor:
National Center of Neurology and Psychiatry, Japan